Page 169 - NobleCon19revC2_Neat

Tonix Pharmaceuticals Holding Corp.

SELECTED FINANCIAL ITEMS TNXP
(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA 3.99 3.99
Gross Profit NA NA NA 1.62 1.62
Gross Margin NM NM NM 40% 40%
EBIT (32.73) (33.90) (29.00) (28.15) (123.78)
EBIT Margin NM NM NM -706% -3103%
Net Income to Common Shareholders (31.68) (33.01) (28.36) (27.98) (121.02)
Net Margin NM NM NM -701% -3034%

Balance Sheet Key Items
Total Assets 225.69 179.09 159.74 139.28 139.28
Cash & Short Term Investments 120.23 71.98 25.62 6.91 6.91
% of Assets 53% 40% 16% 5% 5%
Current Assets -Total 130.78 83.73 51.33 31.34 31.34
% of Assets 58% 47% 32% 22% 22%
Total Liabilities 18.51 13.66 19.27 18.45 18.45
% of Assets 8% 8% 12% 13% 13%
Current Liabilities - Total 18.18 13.07 18.44 17.73 17.73
% of Assets 8% 7% 12% 13% 13%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 207.18 165.43 140.46 120.83 120.83
% of Assets 92% 92% 88% 87% 87%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (22.30) (32.91) (23.37) (23.39) (101.96)
Net Cash Flow - Investing (4.67) (3.80) (24.02) (0.82) (33.31)
Net Cash Flow - Financing 7.23 (11.50) 1.03 6.27 3.03

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference